These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis. Ohno Y; Tokudome K CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712 [TBL] [Abstract][Full Text] [Related]
4. A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release. Tokudome K; Okumura T; Terada R; Shimizu S; Kunisawa N; Mashimo T; Serikawa T; Sasa M; Ohno Y Front Pharmacol; 2016; 7():210. PubMed ID: 27471467 [TBL] [Abstract][Full Text] [Related]
5. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats. Shi J; Zhou F; Wang LK; Wu GF J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628 [TBL] [Abstract][Full Text] [Related]
6. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation. Serajee FJ; Huq AM Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053 [TBL] [Abstract][Full Text] [Related]
7. Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling. Ohno Y; Ishihara S; Terada R; Kikuta M; Sofue N; Kawai Y; Serikawa T; Sasa M Biochem Biophys Res Commun; 2009 Dec; 390(3):415-20. PubMed ID: 19751703 [TBL] [Abstract][Full Text] [Related]
8. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715 [TBL] [Abstract][Full Text] [Related]
9. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357 [TBL] [Abstract][Full Text] [Related]
10. Hippocampal low-frequency stimulation increased SV2A expression and inhibited the seizure degree in pharmacoresistant amygdala-kindling epileptic rats. Wang L; Shi J; Wu G; Zhou F; Hong Z Epilepsy Res; 2014 Nov; 108(9):1483-91. PubMed ID: 25205164 [TBL] [Abstract][Full Text] [Related]
11. Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus. Ohno Y; Okumura T; Terada R; Ishihara S; Serikawa T; Sasa M Neurosci Lett; 2012 Feb; 510(2):93-8. PubMed ID: 22266237 [TBL] [Abstract][Full Text] [Related]
12. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model. Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420 [TBL] [Abstract][Full Text] [Related]
14. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974 [TBL] [Abstract][Full Text] [Related]
15. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats. Ge YX; Lin YY; Bi QQ; Chen YJ Curr Neurovasc Res; 2020; 17(4):354-360. PubMed ID: 32407277 [TBL] [Abstract][Full Text] [Related]
16. Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain. Mendoza-Torreblanca JG; García-Cruz ME; Sánchez-Cruz I; Gomez-Gonzalez B; Juárez-Méndez S; Gómez-Lira G Neuroscience; 2019 Nov; 419():108-120. PubMed ID: 31520710 [TBL] [Abstract][Full Text] [Related]
17. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment. Contreras-García IJ; Gómez-Lira G; Phillips-Farfán BV; Pichardo-Macías LA; García-Cruz ME; Chávez-Pacheco JL; Mendoza-Torreblanca JG Brain Sci; 2021 Apr; 11(5):. PubMed ID: 33922424 [TBL] [Abstract][Full Text] [Related]
18. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Toering ST; Boer K; de Groot M; Troost D; Heimans JJ; Spliet WG; van Rijen PC; Jansen FE; Gorter JA; Reijneveld JC; Aronica E Epilepsia; 2009 Jun; 50(6):1409-18. PubMed ID: 19220410 [TBL] [Abstract][Full Text] [Related]
19. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Gillard M; Chatelain P; Fuks B Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440 [TBL] [Abstract][Full Text] [Related]
20. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE). Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]